GLP-1 receptor agonists (GLP-1 RAs), especially semaglutide, are rapidly emerging not just as weight-loss or diabetes drugs, but as potentially high-impact medical interventions across cardiovascular disease, renal disease, addiction, and women’s health. Given the enormous global burden of cardiometabolic disease, the scale of need, and evolving evidence, this class may warrant serious attention from the EA community (especially those focused on global health, R&D prioritization, and neglected biomedical innovations).

So why could GLP-1s be exceptionally important?

1. Cardiovascular risk reduction in non-diabetic overweight populations

In the SELECT trial — a randomized, double-blind, placebo-controlled study of over 17,600 people (BMI ≥ 27, with established cardiovascular disease but without diabetes) — once-weekly subcutaneous semaglutide (2.4 mg) produced a 20% reduction in major adverse cardiovascular events (MACE) compared to placebo [1, 2].

A prespecified mediator analysis found that part (~33%) of the benefit was mediated via reductions in waist circumference, but importantly, much of the cardiovascular benefit appears to be independent of simple weight loss, implying additional mechanisms [4].

There is also evidence of kidney protection: semaglutide reduced a composite kidney endpoint (eGFR decline, macroalbuminuria, kidney failure, or kidney death) versus placebo in the SELECT kidney analysis [3].

In heart-failure subgroups (both reduced and preserved ejection fraction), semaglutide also lowered MACE and other CV outcomes [4].

2. Emerging evidence in addiction / substance use

• A phase 2 randomized clinical trial in adults with alcohol use disorder (AUD) found that semaglutide significantly reduced alcohol craving and reduced consumption in a lab self-administration paradigm [6].
• Mechanistically, GLP-1 receptors are expressed in reward-related brain regions, and GLP-1 signaling appears to dampen alcohol-related reward responses; this is well supported by preclinical and human mechanistic literature [7, 11].
• Observational real-world data also suggest semaglutide is associated with lower risk of tobacco use disorder (TUD), and with reduced use of smoking-cessation medications compared with users of other antidiabetic medications [5].
• Additional early-stage work (including preclinical research and small clinical investigations) supports GLP-1 RAs as a potential treatment for nicotine addiction [7–9, 11].
• A growing number of clinical trials are underway, including for nicotine use disorder and smoking cessation [7, 9].

These signals suggest a new and potentially important therapeutic pathway for addiction — an area of huge global health burden that is often underfunded.

3. Reproductive / gynecologic applications

A meta-analysis of randomized controlled trials comparing GLP-1 RAs (such as liraglutide) to metformin in women with polycystic ovary syndrome (PCOS) found that GLP-1 RAs improved insulin sensitivity, reduced BMI, and reduced abdominal circumference more than metformin [12].

Because PCOS is highly prevalent and affects metabolic health, fertility, and quality of life, this could represent another meaningful indication with large population impact.

4. Scale and global burden

Cardiometabolic diseases remain among the top global contributors to morbidity and mortality. Even modest relative reductions in risk, when applied at scale, could translate into large population-level health gains.

However, current prices limit access, especially in low- and middle-income countries. This creates potential leverage for EA-aligned philanthropy to help shape price negotiation, licensing, manufacturing, and implementation.

Key Risks, Uncertainties, and Challenges

• Generalizability: Many trials (including SELECT) were conducted in high-income settings; effects in LMIC populations or health systems remain uncertain.
• Adherence & duration: GLP-1s are often chronic therapies; long-term adherence and tolerability affect real-world cost-effectiveness.
• Safety: GI side effects are common; risk–benefit varies by use case.
• Cost & access: Branded GLP-1s remain expensive; global access will depend on generics, voluntary licensing, or negotiated pricing.
• Ethical and equity considerations: Should GLP-1s be prioritized for secondary prevention, addiction treatment, obesity treatment, or something else? Allocation frameworks are needed.

Priority Actions

1. Modelling & cost-effectiveness analyses

• Build DALY/QALY models for cardiometabolic outcomes incorporating the SELECT MACE results, renal outcomes, and potential addiction benefits.
• Estimate cost per DALY averted under multiple price scenarios (current list price, negotiated price, generic).
• Compare against top EA-funded interventions to understand relative priority.

2. Targeted clinical trials

• Fund or co-fund addiction trials, especially for alcohol use disorder, nicotine use disorder, and stimulant addiction.
• Support pragmatic implementation trials in LMICs or diverse real-world populations.
• Sponsor women’s health trials to better understand impacts in PCOS, fertility, and broader metabolic-reproductive interactions.

3. Access, manufacturing & policy work

• Pursue voluntary licensing or tech-transfer models to speed generic manufacturing.
• Support policy analysis for potential inclusion on WHO or national essential medicines lists (contingent on cost).
• Pilot bulk procurement or price-negotiation frameworks in collaboration with ministries of health.

4. Ethics and allocation frameworks

• Support development of fair, evidence-based guidelines for GLP-1 allocation, including prioritization for high-risk cardiometabolic patients or addiction treatment.
• Explore equity frameworks to prevent widening global disparities in access.

Why This Is Underserved in EA Right Now

• Despite the massive global burden of NCDs, EA discussions often focus on infectious diseases or catastrophic risks; comparatively little attention goes to cardiometabolic innovations.
• GLP-1s might represent a platform therapeutic with broad, multi-indication benefits. This kind of scalable medical technology that can have long-run implications on population health.
• There is real tractability: evidence is strong, mechanisms plausible, and actionable levers exist for research, access, and policy.

Call to Action & Questions for the EA Community

• Which of the proposed actions (modeling, trials, access work) should be explored first?
• Are EA-aligned funders (e.g., @Coefficient Giving , @GiveWell ) already exploring  GLP-1–related work?
• Which assumptions most affect cost-effectiveness estimates?
• Would a community working group on GLP-1s for global health help move this forward?

GLP-1 receptor agonists like semaglutide could represent a transformative advance in population health. Early evidence indicates benefits across cardiovascular outcomes, kidney disease, addiction, and women’s health. If cost barriers can be reduced and access expanded, these medicines may become among the most cost-effective interventions available at scale. For the EA community, this appears to be a promising, actionable, and currently neglected opportunity for impact.

Works Cited

1. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes. New England Journal of Medicine. (SELECT trial).
2. American College of Cardiology. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT).
3. Zhuo X et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease: SELECT kidney analysis.
4. Lincoff AM et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: prespecified SELECT analysis.
5. Wang W et al. Association of Semaglutide With Tobacco Use Disorder in Real-World Data.
6. Hendershot CS et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.
7. Herman RJ et al. GLP-1 receptor agonists as therapeutic targets in substance use disorders.
8. Jain V. Glucagon-like Peptide-1 Agonists and Smoking Cessation: Brief Review.
9. Yammine L et al. Semaglutide for weight management in the context of smoking cessation.
10. Endocrine Society. GLP-1s show promise in treating alcohol and drug addiction.
11. Endocrinology Review Article: GLP-1 Pathways in Substance Use Disorders.
12. Zhang J et al. GLP-1 receptor agonists versus metformin in polycystic ovary syndrome: meta-analysis of RCTs.